Luxturna Market Report 2026

Luxturna Market Overview

• The Luxturna market growth in the historic period has been driven by limited treatment options for inherited retinal diseases, advancements in viral vector technology • Market expansion is supported by expansion of gene therapy pipelines, rising investments in rare disease treatments • Growth Driver: Growing Prevalence Of Genetic Eye Disorders And Advances In Gene Therapy • Market Trend: Real-World Data And Efficacy Of Luxturna • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Luxturna Market?

Luxturna is a gene therapy treatment used to treat patients with inherited retinal diseases caused by mutations in the RPE65 gene, which can lead to vision loss and blindness. It delivers a functional copy of the RPE65 gene directly into the retinal cells, allowing them to produce a protein necessary for vision. The main types of indications for luxturna include treatment of RPE65-mediated inherited retinal disease and management of vision loss. Treatment of RPE65-mediated inherited retinal disease targets genetic mutations in the RPE65 gene that cause progressive vision loss and blindness, and Luxturna, a gene therapy, is delivered via subretinal injection to provide a functional RPE65 gene, improving vision in eligible patients. The patient demographics include pediatric patients, adult patients, and patients with early diagnosis, and distribution channels are categorized into direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies for end users such as hospitals, ophthalmology clinics, specialty pharmacies, and research institutions.

What Is The Luxturna Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of gene therapy pipelines, rising investments in rare disease treatments, growing adoption of early genetic screening, increasing focus on long-term treatment outcomes, advancements in retinal delivery technologies. Major trends in the forecast period include increasing adoption of gene therapy treatments, rising focus on rare genetic eye disorders, growing investment in one-time curative therapies, expansion of precision ophthalmology solutions, enhanced integration of genetic screening and diagnosis.

Global Luxturna Market Segmentation

1) By Indication: Treatment Of RPE65-Mediated Inherited Retinal Disease, Management Of Vision Loss 2) By Patient Demographics: Pediatric Patients, Adult Patients, Patients With Early Diagnosis 3) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies 4) By End User: Hospitals, Ophthalmology Clinics, Specialty Pharmacies, Research Institutions

What Are The Drivers Of The Luxturna Market?

The rising prevalence of genetic eye disorders is expected to propel the growth of the luxturna market going forward. Genetic eye disorders refer to a range of inherited conditions caused by gene mutations that affect the eyes' structure or function, leading to visual impairments such as blindness or reduced vision. The rising prevalence of genetic eye disorders can be attributed to increased genetic mutations, aging populations, improved diagnostic technologies, and a greater awareness of hereditary conditions. Luxturna is a gene therapy used to treat genetic eye disorders, specifically inherited retinal diseases (IRDs) caused by mutations in the RPE65 gene, offering a potential cure by delivering a functional copy of the gene to restore vision. For instance, in December 2023, according to the United Nations Development Programme (UNDP), a US-based government agency, the number of individuals diagnosed with vision impairments was 19,551 in 2022. Moreover, over 19,000 new diagnoses were reported in just the first seven months of 2023. Therefore, the rising prevalence of genetic eye disorders is driving the growth of the luxturna industry. The rise in healthcare expenditure is expected to drive the luxturna market going forward. Healthcare expenditure is the total amount spent on medical services, treatments, and products by governments, businesses, or individuals. Healthcare expenditure is rising due to factors like aging populations, advancements in medical technology, increased prevalence of chronic diseases, and rising treatment costs. Rising healthcare expenditure supports Luxturna by enabling the funding and accessibility of advanced treatments like gene therapy for rare inherited retinal diseases, which are often expensive and require specialized care. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, marking a significant rise compared to the 0.9% growth seen in 2022. Therefore, a rise in healthcare expenditure will fuel the growth of the luxturna industry.

Key Players In The Global Luxturna Market

Major companies operating in the luxturna market are F. Hoffmann-La Roche AG

Global Luxturna Market Trends and Insights

A key trend in the luxturna market is conducting real-world studies for its gene therapies, such as adeno-associated virus vector-based gene therapy, to establish a reputation for transparency and commitment to patient outcomes. Adeno-associated virus (AAV) vector-based gene therapy uses a modified virus to deliver therapeutic genes to cells, offering treatment for genetic diseases like RPE65-related retinal dystrophy. For instance, in April 2023, Spark Therapeutics, a US-based biotechnology company specializing in gene therapy treatments, demonstrated real-world data for Luxturna (voretigene neparvovec), an AAV-based gene therapy for RPE65-related inherited retinal dystrophy (IRD), from 8 Belgian patients presented at the ARVO 2023 Annual Meeting. Among 15 treated eyes in the observational study, significant light sensitivity improvements were observed 6 months post-treatment for red, blue, and white light and enhancements in the visual field (object III4). At 2 years post-treatment, Luxturna showed a mean change of -0.03 BCVA and -13.67 decibels in the full-field light sensitivity threshold. Regarding safety, 35% of patients experienced at least one ocular adverse event, with chorioretinal atrophic changes being the most common, reported in 13 cases.

Regional Insights

North America was the largest region in the luxturna market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Luxturna Market?

The luxturna market consists of sales of diagnostic kits, ocular imaging devices, cell therapy products, ophthalmic surgical instruments, retinal imaging systems, and patient monitoring devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Luxturna Market Report 2026?

The luxturna market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the luxturna industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.